Commentary
Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics
Ari Breiner, Lorne Zinman and Pierre R. Bourque
CMAJ March 23, 2020 192 (12) E319-E320; DOI: https://doi.org/10.1503/cmaj.191236
Ari Breiner
Division of Neurology (Breiner, Bourque), Department of Medicine, The Ottawa Hospital and University of Ottawa; Ottawa Hospital Research Institute (Breiner, Bourque), Ottawa, Ont.; Sunnybrook Research Institute (Zinman), Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre; Division of Neurology (Zinman), Department of Medicine, University of Toronto, Toronto, Ont.
MD, MScLorne Zinman
Division of Neurology (Breiner, Bourque), Department of Medicine, The Ottawa Hospital and University of Ottawa; Ottawa Hospital Research Institute (Breiner, Bourque), Ottawa, Ont.; Sunnybrook Research Institute (Zinman), Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre; Division of Neurology (Zinman), Department of Medicine, University of Toronto, Toronto, Ont.
MD, MScPierre R. Bourque
Division of Neurology (Breiner, Bourque), Department of Medicine, The Ottawa Hospital and University of Ottawa; Ottawa Hospital Research Institute (Breiner, Bourque), Ottawa, Ont.; Sunnybrook Research Institute (Zinman), Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre; Division of Neurology (Zinman), Department of Medicine, University of Toronto, Toronto, Ont.
MDIn this issue
Article tools
Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics
Ari Breiner, Lorne Zinman, Pierre R. Bourque
CMAJ Mar 2020, 192 (12) E319-E320; DOI: 10.1503/cmaj.191236
Related Articles
- No related articles found.
Cited By...
- No citing articles found.